Corticose nsitivity in¯uence s the degree and the duration of an in¯ammatory re action by alte ring targe t cell re sponse s to endoge nous and/or exoge nous glucocorticoid s. Inde e d, differe nt clinical re sponse s to glucocorticoid s have be en observe d among patie nts with Crohn' s disease , sugge sting diffe rent de gre es of corticose nsitivity in the se subje cts. The purpose of this study was to compare the corticose nsitivity of patie nts with quie scent Crohn' s dise ase to that of he althy subje cts (HS). Nine tee n patie nts with quie scent Crohn' s disease and 14 HS were studie d; all patie nts were ste roid-fre e for at least six months; 7 of the 19 were corticoste roid-de pende nt (CSD) and treate d with nonglucocortic oid immunosupp ressants at the time of the study. Corticose nsitivity was measure d by the inhibition of LPS-induce d cytokine se cretion in whole blood cell culture s tre ate d with incre asing conce ntrations (10 2 9 to 10 2 6 M) of de xame thasone . Tumor-ne crosis factor-a (TNF-a ), interle ukin-6 (IL-6), and interleukin-1b (IL-1b ) were measure d using spe ci® c immunoassays. Crohn' s dise ase patie nts had a marke dly decrease d dexamethasone -mediate d inhibition of TNF-a (P , 0.01) , IL-6 (P , 0.001) , and IL-1b (P , 0.01) compare d to he althy subje cts, with a shift of the dexame thasone dose ± response curve to the right. No signi® cant diffe rences in the basal and LPS-stimulate d secretion of the thre e cytokine s were obse rved betwe en CSD and non-CSD patie nts, and both subgroups of patie nts had similar de gre es of dexame thasone -mediate d cytokine inhibition. We conclude that patie nts with Crohn' s disease have a signi® cant decrease in the corticose nsitivity of the ir le ukocyte s. This may be re late d to a spe ci® c ge netic/constitutio nal background and/or could be acquire d, due to in¯ammation-re late d e ndocrine and/or immune factors.
tory and immunosuppre ssive drugs in many in¯ammatory and autoimmune dise ase s (6) . Diffe rent clinical response s to glucocorticoids have be e n observe d among patie nts suffering from such dise ase s, and patie nts with Crohn' s disease have be en classi® e d as corticoste roid-se nsitive (when a good response to tre atme nt is obse rve d) , corticoste roid-de pe nde nt (CSD) (when glucocorticoids are ne ede d to ke ep the in¯ammatory disease quie scent), and corticoste roidre sistant (CSR) (whe n the y are not re sponsive to glucocorticoid treatme nt). The pre vale nce of corticoste roid de pende ncy in Crohn' s disease is about 15± 35% (7± 9), while corticoste roid re sistance is observe d in less than 10% of the patie nts (9, 10) .
Corticose nsitivity depe nds not only on the glucocorticoid receptor (GR) number and af® nity, but also on pre -and postre ceptor mechanisms of GR activation, including the inte ractions of GR with cytoplasmic and nucle ar factors and spe ci® c DNAre sponsive e le ments (11, 12) . O nly a few clinical studies have be en carrie d out on corticose nsitivity and none in Crohn' s dise ase . Familial glucocorticoid resistance was studie d by Chrousos e t al (13) and Lamberts e t al (14) and was shown to be of ge netic e tiology and relate d to a de crease of GR af® nity for its ligand or to a de crease in GR numbe r pe r cell (13, 14) . She r et al (15) de scribed two populations of corticoste roid-re sistant (CSR) asthm a patie nts: type 1 is de ® ned by de crease d GR af® nity binding, and type 2 is de ® ne d by decreased GR number per cell. Type 1 CSR asthma was shown to be reve rsible and secondary to in¯ammation, while type 2 CSR asthma appe are d to be gene tically and/or constitutionally de te rmined (15) . Finally, Schlaghe cke e t al re porte d a 50% de crease of GR number/ce ll in patie nts with rheumatoid arthritis (16) ; howeve r, inexplicably, this did not appe ar to in¯ue nce the in vitro corticose nsitivity of these patie nts (17) .
Whole blood cell culture is an appropriate ex vivo te chnique to analyze corticose nsitivity within a controlle d e nvironme nt, by studying the inhibition of cytokine se cretion by grade d concentrations of glucocorticoids (18) . The aim of this work was to compare corticose nsitivity betwe en patie nts with quie scent Crohn' s disease and he althy control subje cts.
MATERIALS AND METHODS

Patients an d Con trols.
Patie nts with Crohn's disease (10 women and 9 men) and healthy volunteers (7 women and 7 me n) serve d as blood donors. The me an age was 35 years in patients with Crohn's disease (range : 20 ± 53 years) and 33 ye ars in controls (range: 24 ± 44 ye ars). The clinical charac-teristics of patients with Crohn's disease are summarized in Table 1 . All patients with quiescent Crohn's disease we re followed in the Gastroe nterology Division at the Unive rsity Hospital of LieÁ ge , Belgium. The diagnosis of Crohn's dise ase was made by classical clinical, radiological, and e ndoscopic criteria. Seven of the 19 patie nts we re corticosteroiddependent. The corticoste roid dependency was de® ned e ither by two successive relapses following glucocorticoid discontinuation or by two successive relapses at dose tape ring afte r a successful treatme nt of a¯are-up with glucocorticoids (7, 8, 19) . Treatme nt with immunosuppressive drugs (azathioprine or me thotrexate ) allowed the complete withdrawal of glucocorticoids in these patie nts. Nine non-CSD patients were treate d with 5-aminosalicylic acid (5-ASA). All patients studied were in clinical remission and corticosteroid-free for at least six months. Three groups we re de® ned: non-corticosteroid-dependent (non-CSD) patients; corticosteroid-dependent (CSD) patients; and healthy controls (HS). Data from the interleukin-1b (IL-1b ) assay of four CSD patients and two non-CSD patie nts we re not included. Similarly, data from the tumor necrosis factor-a (TNF-a ) assay of one CSD patient and one non-CSD patient we re not included because of absence of stimulation by LPS.
Wh ole Blood Cell Cultures. The blood was tre ate d as previously described (18) . Blood samples we re collected in apyroge nic he parinized tubes provided by Biosource / Medge nix (Fleurus, Belgium). The white blood cell count was in the normal range in CD patients. The blood was processed imme diate ly and diluted with 1/10 RPMI 1640 supplemente d with 2 mM glutamine, 100 IU/ml penicillin, 100 m g/ml streptomycin (Biowitthaker), and was then distributed in 2-ml wells. RPMI 1640 medium was tested for apyroge nicity. LPS (endotoxin from Salmonella enteritidis; Sigma, St. Louis, Missouri) was adde d at a ® nal concentration of 25 pg/ml. A synthetic glucocorticoid, dexame tha- to 10 2 6 M in separate we lls. Plates were incubated at 37°C in a 5% CO 2 athmosphere; the incubation time was 24 hr for LPS-stimulated whole blood cell cultures (18, 20) . The contents of the we lls were the n collected and centrifuged at 900g for 10 minutes. Supernatants we re recovered and frozen at 2 20°C. Blood was drawn from women during the proliferative phase of the ir cycle. Im m un oas says . TNF-a , IL-1b , and IL-6 we re me asured with speci® c immunoassays from Biosource/Medgenix without any cross-reactivity. Immunoassays we re performed according to the manufacturer's directions. The dete ction limit was 3 pg/ml for TNF-a , 2 pg/ml for IL-1b , and 2 pg/ml for IL-6. Plate s we re read at 460 nm by a microplate ELISA reade r from Medge nix Diagnostics. Absorbancy was transformed to cytokine concentration using a standard curve computed by Medgenix ELISA software . Plasma cortisol (RIA, Immunotech, Marseille, France) and cortisol-binding globulin (RIA, Radim, Liege, Belgium) we re me asured with the routine laboratory methods. The blood was collected from each individual betwe en 3 and 6 PM. The blood was then processed immediately for whole blood cell cultures. Plasma obtained at the same time was frozen at 2 20°C until assay. Once all the plasma samples from the patients and the healthy subjects we re collecte d, cortisol and cortisol binding globulin concentrations we re me asured in a single batch.
Statis tical Analyses. Statistical analyse s were carried out using the SAS software package (SAS Institute Inc., Cary, North Carolina). The relative changes in cytokine production were computed for e ach dose of dexame thasone. A log transformation was used for both the absolute values of cytokine production and for the percentage of the response in each individual to normalize the distribution of the data. A ge neralized linear mixe d model with random effe cts (SAS Proc Mixed) was ® tted to study the dexame thasone ge neral e ffe ct and dose effect on cytokine secretion. All results we re considered to be signi® cant at the 5% critical level (P , 0.05). The SAS Proc Mixe d is an ANOV A for repeate d me asures, as is appropriate where the observations in the same subject are not independent of e ach other. This me thod adjusts the standard error as a function of the covariance structure of the observations. The ED 5 0 was calculated as the dose of dexame thasone necessary to produce a 50% inhibition in the secretion of e ach of the three cytokines for e ach individual, using the SAS Proc Mixed program. The statistical comparisons we re betwe en the me ans of the ED 5 0 s in the three groups of subjects with the Kruskal-Wallis and the Wilcoxon tests.
Othe r statistical comparisons within the same group or betwe en the three groups we re performed using nonparame tric (Kruskal-Wallis and Wilcoxon tests) and parametric tests (ANO V A and Student t tests afte r a logarithmic transformation).
RESULTS
Cytokin e Secretion in Wh ole Blood Secretion from CD Patien ts an d Health y Su bjects
The re was a signi® cant differe nce in cytokine se cretion betwe en basal and LPS-induce d le ve ls of cytokine s in the non-CSD patie nts (P , 0.001 for TNF-a , IL-6, and IL-1b ), in CSD patie nts (P , 0.001 for TNF-a and IL-6, P , 0.01 for IL-1b ), and in he althy subje cts (P , 0.001 for TNF-a , IL-6, and IL-1b ) ( Table 2) .
Basal cytokine leve ls in whole blood cell culture s were similar in both groups of patie nts with Crohn' s disease and he althy subje cts. LPS-stim ulate d IL-6 and TNF-a leve ls were signi® cantly differe nt betwe en CD patie nts and he althy subje cts (P , 0.05 and P , 0.05, re spective ly) and be twee n CSD patie nts and he althy subje cts (P , 0.05 and P , 0.05, respe ctively) . No diffe rence was obse rved be twee n non-CSD patie nts and he althy subje cts ( Table 2) .
Inh ibition of Cytokin e Secretion by Dexam eth ason e in Wh ole Blood Cell Cu ltu res from CD Patien ts an d Health y Su bjects
The re sults of the conce ntration-de pe nde nt e ffe ct of de xame thasone on TNF-a , IL-6, and IL-1b se cretion in whole blood cell culture s in the thre e groups are shown in Figure s 
TNF-a .
There was a signi® cant inhibition of TNF-a se cretion by dexamethasone from 10 2 8 to 10 2 6 M in he althy subje cts (P , 0.001) , in non-CSD patie nts (P , 0.001) , and in CSD patie nts (P , 0.001). While there was a signi® cant inhibition of TNF-a secretion by dexame thasone at 10 2 9 M in he althy subje cts (P , 0.001) , no inhibition was observe d in non-CSD or CSD patie nts. IL-6. The re was a signi® cant inhibition of IL-6 se cretion by dexamethasone from 10 2 8 to 10 2 6 M in he althy subje cts (P , 0.001) and in non-CSD (P , 001) and in CSD patie nts (P , 0.001) . While the re was a signi® cant inhibition of IL-6 se cretion by de xamethasone at 10 2 9 M in he althy subje cts (P , 0.001) , no inhibition was obse rved in non-CSD or CSD patie nts. IL-1b . The re was a signi® cant inhibition of IL-1b se cretion by dexamethasone from 10 2 8 to 10 2 6 M in he althy subje cts (P , 0.001) and in non-CSD (from P , 0.01 to P , 0.001) and in CSD patie nts (from P , 0.06 to P , 0.001) . While there was a signi® cant inhibition of IL-1b secretion by de xame thasone at 10 2 9 M in he althy subje cts (P , 0.05) , no inhibition was observe d in non-CSD or CSD patie nts.
Plas m a Cortisol an d Cortisol-Bin din g Globu lin Levels in CD Patien ts an d Health y Su bjects
Plasma cortisol (112.6 6 6.5 vs 120.6 6 12.2 m g/dl, re spective ly) and cortisol-binding globulin (28.1 6 1.3 vs 25 6 1.3 m g/ml, re spe ctive ly) leve ls were similar in CD patie nts and healthy subje cts. Plasm a cortisol (120 6 10.1 vs 104.5 6 7.5 m g/dl, re spe ctive ly) and cortisol-binding globulin (25.3 6 2.0 vs 31.3 6 2.8 m g/ml) were also similar in non-CSD and CSD patie nts. 
Assessm ent of Corticos en sitivity in CD Patien ts an d Health y Su bjects
The top pane ls of Figure s 1± 3 show the mean pe rcentage of inhibition of cytokine production by de xame thasone in the three groups, taking into account the O-dexamethasone conce ntration (cytokine leve l after LPS stimulation) , which is the re fere nce for each individual (Figure s 1A, 2A, and 3A) .
TNF-a . A signi® cant differe nce be twee n all patie nts with Crohn' s disease and controls was observe d in the gene ral patte rn of TNF-a inhibition by de xamethasone (P , 0.01) . A signi® cant differe nce also was obse rved betwe en all patie nts and controls in the rate of TNF-a inhibition by de xamethasone at 1 nM (P , 0.05) , 10 nM (P , 0.01) and 100 nM (P , 0.05) .
There was a slight, but nonsigni® cant, diffe rence at 1 m M of dexame thasone be twee n all patie nts and controls (P , 0.052) ( Figure 1A) .
A diffe rence was obse rved in the rate of TNF-a inhibition betwe en non-CSD patie nts and controls by de xame thasone at 1 nM and 10 nM (P , 0.01) . A similar diffe rence was observe d in the rate of TNF-a inhibition betwe e n CSD patie nts and controls by de xame thasone at 1 nM and 10 nM (P , 0.01) and from 100 nM to 1 m M (P , 0.05) ( Figure 1A) .
IL-6.
A signi® cant diffe re nce betwe en all patie nts and controls was observe d in the gene ral patte rn of IL-6 inhibition by de xame thasone (P , 0.001) . A signi® cant diffe rence in IL-6 inhibition also was obse rved be twee n all patie nts and controls at 1 nM (P , 0.01) and from 10 nM to 1 m M of de xame thasone (P , 0.001) (Figure 2A) .
The re was a differe nce in the rate of IL-6 be twee n non-CSD patie nts and controls by dexame thasone at 1 nM (P , 0.01) and from 10 nM to 1 m M (P , 0.001) . A differe nce also was obse rve d be twee n CSD patie nts and controls by de xame thasone at 1 nM (P , 0.05) and from 10 nM to 1 m M (P , 0.001) ( Figure   2A ).
IL-1b .
A signi® cant diffe rence be twee n all patie nts with Crohn' s dise ase and controls was obse rved in the gene ral patte rn of IL-1b inhibition by de xame thasone (P , 0.01) . A diffe re nce betwe en all patie nts and controls also was observe d in the rate of IL-1b inhibition by de xame thasone at 10 nM (P , 0.01) and at 100 nM (P , 0.05) . The re was a slight, but nonsignificant, diffe rence at 1 nM betwe en all patie nts and controls (P 5 0.092) ( Figure 3A) .
A signi® cant diffe rence in the rate of IL-1b inhibition was obse rved be twee n non-CSD patie nts and controls by de xame thasone at 10 nM (P , 0.01) .
There was a signi® cant differe nce in the rate of IL-1b inhibition by dexame thasone be twee n CSD patie nts and controls at 10 nM (P , 0.01) and at 1 m M (P , 0.05) . The re was a slight, but nonsigni® cant, diffe re nce at 1 nM of de xamethasone betwe en non-CSD patie nts and CSD patie nts versus controls (P 5 0.15 and P 5 0.16, re spe ctive ly) ( Figure 3A) .
Inte re stingly, no signi® cant diffe re nce be twe e n non-CSD and CSD patie nts was obse rved in the de xamethasone gene ral and dose effe ct on cytokine se cretion (Figure s 1A, 2A, and 3A) .
The IC 50 s of dexamethasone e ffe cts on the se cretion of the three in¯ammatory cytokine s are reporte d on Table 3 . The re was a global signi® cance be twee n patie nts with Crohn' s disease and HS for TNF-a (P , 0.01) , IL-1b (P , 0.01) , and IL-6 (P , 0.001) . The re were no signi® cant diffe rence s betwe e n non-CSD patie nts and CSD patie nts for each of the thre e cytokine s. The re was no signi® cant diffe re nce in the inhibition of TNF-a se cretion by dexame thasone betwe en CD patie nts and he althy subje cts or be twee n the thre e groups ( Figure 1B) . The re was a signi® cant differe nce in the inhibition of IL-6 se cretion by de xame thasone at 100 nM and 1 m M be twee n CD patie nts and he althy subje cts (P , 0.01 and P , 0.01, respectively) .
A signi® cant diffe rence in the inhibition of IL-6 secretion also was obse rved at 1 m M of de xame thasone betwee n non-CSD and he althy subje cts and be twee n CSD patie nts and healthy subje cts (P , 0.01) ( Figure   2B ). The re was a signi® cant differe nce in the inhibition of IL-1b secretion by dexame thasone at 100 nM and 1 m M betwe en CD patie nts and he althy subje cts (P , 0.01 and P , 0.01, respe ctively) . A signi® cant diffe rence also was obse rved at 100 nM and 1 m M betwee n CSD patie nts and healthy subje cts (P , 0.05 and P , 0.01, re spe ctive ly) ( Figure 3B ).
DISCUSSION
The corticose nsitivity of patie nts with Crohn' s dise ase and control subje cts was evaluate d in this study by the de gre e of inhibition of cytokine secretion in whole blood cell culture s by grade d conce ntrations of de xame thasone . The data sugge sted a signi® cant decre ase in the corticose nsitivity of patie nts with Crohn' s dise ase . The re was no differe nce be twee n CSD patie nts and non-CSD patie nts, howeve r. All of our patie nts in this study were in clinical remission (Crohn' s disease activity inde x , 150) and corticosteroid-fre e for at le ast six months. Pre vious studie s on steroid-se nsitive and ste roid-re sistant asthma were carried out in patie nts concurre ntly re ceiving glucocorticoid the rapy (15, 21, 22) . Glucocortic oids normally induce a down-re gulation of GR, and this could lead to a decrease in corticose nsitivity. Thus, a study of corticose nsitivity in patie nts treate d with e xogenous glucocorticoid s may re¯ect treatme nt rathe r than disease effect. The comple te abste ntion from glucocorticoid s for at least six months in non-CSD patie nts and in CSD patie nts tre ate d with immunosuppre ssants allowe d us to avoid this pote ntial pitfall.
Inte rle ukin-1b , IL-6, and TNF-a are important cytokine s of innate immunity and mediate both speci® c and nonspe ci® c in¯ammatory re sponse s. These cytokine s are also important mediators of in¯ammation in the inte stinal mucosa of patie nts with in¯ammatory bowe l diseases. Enhance d se cretion of such cytokine s by periphe ral blood mononucle ar cells (PBMCs) was re porte d in patie nts with Crohn' s dise ase e arlie r (23) . We did not con® rm this, but rathe r de monstrate d that the basal production of in¯ammatory cytokine s ex vivo was not differe nt from that of controls and that afte r LPS stimulation, the production of TNF-a and IL-6 was, in fact, decrease d in CSD patie nts compare d to those of he althy subje cts. This could be e xplaine d by the diffe rent methodologie s use d and the type of subje ct populations studie d. All the CSD patie nts were tre ate d with immunosuppre ssants.
The de crease d PBMC corticose nsitivity of patie nts with Crohn' s disease might be relate d to the in¯ammatory state itse lf. Inde ed, corticose nsitivity was earlie r shown to be modulate d by cytokine s (24) . Some proin¯ammatory cytokine s, such as IL-1b , IL-6, TNF-a and interferon-g (IFN-g ), increased (24 ± 26) , while othe r mostly antiin¯ammatory cytokine s, such as IL-4 and IL-13, decreased se nsitivity to glucocorticoids, possibly glucocorticoid re ceptor numbe r and af® nity change s (27, 28) . Glucocorticoids are pote nt inhibitors of NF-k B, a pivotal transcription factor for the expre ssion of many cytokine ge nes in chronic in¯ammatory dise ase s (29, 30) . NF-k B functions as an intrace llular ampli® cation factor that e xace rbate s chronic in¯ammatory proce sses and itse lf inhibits the activity of the ligand-bound glucocorticoid re ceptor (31) . Exce ssive NF-k B induction thus could pre vent glucocorticoid suppre ssion and could contribute to a de crease in corticose nsitivity (32) .
The susce ptibility to de ve lop an in¯ammatory dise ase could also be re late d to a gene tically and/or constitutionally de termined de crease in corticose nsitivity. Type 2 CSR asthma was shown to be relate d to a primary decrease of GR numbe r pe r cell (15) . Hypose nsitivity could le ad to an hype rimmune state and to susceptibility to in¯ammatory and autoimmune dise ase s (11, 12) . A primary decrease in corticose nsitivity could re sult in a relative inability of e ndoge nous glucocorticoids to modulate the mucosal immune re sponse to bacte rial or alime ntary luminal antige ns, supe rantige ns, and nonspe ci® c immunostimulants. This study sugge sts that decrease d corticose nsitivity in patie nts with quie scent Crohn' s dise ase might be a factor favoring furthe r re lapse s. A pote ntial e ffect of the tre atme nt with 5-ASA or azathioprine could not be e xclude d. Whether such a tre atment could directly in¯ue nce corticose nsitivity is, howe ver, uncle ar. The patte rn and degree of de xamethasone -mediate d inhibition were the same in quie scent CSD and quie scent non-CSD patie nts. O n one hand, this could mean that corticoste roid depe nde ncy in Crohn' s disease is not re late d to a decrease of corticose nsitivity. O n the othe r hand, the same corticose nsitivity in both groups might be due to the immunosupp re ssants improving the corticose nsitivity of CSD patie nts with Crohn' s disease (33) .
Recently, the activity of the HPA axis itse lf was shown to be alte red in in¯ammatory diseases such as rhe umatoid arthritis (34) . Chikanza et al reporte d that rhe umatoid arthritis patie nts had normal cortisol leve ls and a normal response to exoge nous corticotropin rele asing factor but a re duce d re sponse to increase d leve ls of circulating IL-1 and IL-6 induce d by surgical stre ss, compare d to patie nts with oste oarthritis and chronic oste omye litis also unde rgoing a major ope ration (34) . Similarly, early untre ated patients with rhe umatoid arthritis had paradoxically normal ACTH and cortisol le vels, which would not have bee n pre dicted by the ir pain, feve r, and high leve ls of in¯ammatory cytokine s (35) . In our patie nts, hype rcortisolism could be associate d with a de crease in corticose nsitivity via homologous down-re gulation of the GR. The HPA axis of patie nts with Crohn' s disease has not bee n studie d exte nsive ly as ye t; howe ver, our normal base line measure ments of cortisol and cortisol-binding globulin in this study do not corroborate the ide a of a major change in the activity of the HPA axis in Crohn' s disease, ye t furthe r studie s ne ed to be done to rule out subtle or dynamic change s of the ir axis.
In conclusion, a de crease of corticose nsitivity in whole blood cell culture s was obse rved in patie nts with Crohn' s disease compare d to he althy controls. The alte ration of corticose nsitivity in Crohn' s dise ase could be ge ne tic/constitutio nal and/or acquire d in re sponse to e ndocrine and/or immune factors re late d to the in¯ammatory dise ase . Furthe r studie s are ne ede d to characte rize the complex inte ractions betwe en the HPA axis and the immune syste m in inammatory bowe l dise ase s.
